Monday, December 2, 2024
Home Client Page 35

Client

    Most popular

    NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

    Client Editor / Curator -
    Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...

    GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

    Client Editor / Curator -
    Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

    GeoVax Receives Massive $300+ Million BARDA Project NextGen Award!

    Client Editor / Curator -
    Are we happy, you betcha! We just got back from St Croix where the team from the Beverage Stock...

    Nine Page Summary Report on GeoVax (GOVX)

    Client Editor / Curator -
    This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

    GeoVax (GOVX) Provides First Half 2024 Business Update.

    Client Editor / Curator -
    Award of BARDA Project NextGen contract represents a significant milestone event; Total value...
    1...333435Page 35 of 35

    Latest article

    Nine Page Summary Report on GeoVax (GOVX)

    Client Editor / Curator -
    This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

    GeoVax (GOVX) Provides First Half 2024 Business Update.

    Client Editor / Curator -
    Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

    Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

    All News Editor / Curator -
    Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.